About Ovensa

Ovensa Inc. is a Canadian, preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform, with mucosal and brain-barrier crossing properties, to generate advanced nanotherapeutics that enhance the bioavailability and the targeted intracellular uptake of small molecules and biologics through oral and other routes of administration.

Latest News

Montreal, January 12, 2015 – Aligo is proud to announce the granting of a worldwide exclusive license for all applications to Ovensa Inc. for the production and commercialization of trimethyl chitosan (TMC), a derivative of chitosan, a technology emanating from the University du Québec à Rimouski (UQAR).
View full press release...